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HistopathologyPurpose: To demonstrate the feasibility and to evaluate the tumour control probability (TCP) and normal
tissue complication probability (NTCP) of IMRT dose painting using 68Ga-HBED-CC PSMA PET/CT for tar-
get delineation in prostate cancer (PCa).
Methods and materials: 10 patients had PSMA PET/CT scans prior to prostatectomy. GTV-PET was gener-
ated on the basis of an intraprostatic SUVmax of 30%. Two IMRT plans were generated for each patient:
Plan77 which consisted of whole-prostate IMRT to 77 Gy, and Plan95 which consisted of whole-prostate
IMRT to 77 Gy and a simultaneous integrated boost to the GTV-PET up to 95 Gy (35 fractions). The fea-
sibility of these plans was judged by their ability to adhere to the FLAME trial protocol. TCP-histo/-PET
were calculated on co-registered histology (GTV-histo) and GTV-PET, respectively. NTCPs for rectum
and bladder were calculated.
Results: All plans reached prescription doses whilst adhering to dose constraints. In Plan77 and Plan95
mean doses in GTV-histo were 75.8 ± 0.3 Gy and 96.9 ± 1 Gy, respectively. Average TCP-histo values for
Plan77 and Plan95 were 70% (range: 15–97%), and 96% (range: 78–100%, p < 0.0001). Average TCP-PET val-
ues for Plan77 and Plan95 were 55% (range: 27–82%), and 100% (range: 99–100%, p < 0.0001). There was no
significant difference between TCP-PET and TCP-histo in Plan95 (p = 0.25). There were no significant dif-
ferences in rectal (p = 0.563) and bladder (p = 0.3) NTCPs.
Conclusions: IMRT dose painting using PSMA PET/CT was technically feasible and resulted in significantly
higher TCPs without higher NTCPs.
 2017 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 123 (2017) 472–477For radiotherapy (RT) of primary prostate cancer (PCa) a dose–
response relationship between RT dose and tumour control rates is
described. A meta-analysis postulated that the total dose of RT
reduces the risk of biochemical failure by approximately 1.8% per
Gy increase [1]. However, due to the proximity to rectum and blad-
der an unlimited dose escalation to the whole prostatic gland with
external beam RT would entail an unacceptably high risk of severe
toxicity [2]. Previous planning studies simulated the use of focal
dose escalation on a sub-volume within the prostate, which was
defined by dynamic contrast-enhanced magnetic resonanceimaging (MRI), MR spectroscopy [3] or 11C–choline PET/CT [4].
The latter study reported a tumour control probability (TCP) of
97% when an IMRT boost of 90 Gy was delivered to a gross tumour
volume (GTV) based on 70% of SUVmax [4]. However, two more
recent studies reported poor performance for choline PET/CT in
PCa detection and delineation [5,6]. A multicentre, randomized
trial (FLAME-trial) defined the intraprostatic boost volume by mul-
tiparametric MRI (mpMRI) [7]. The control group received 77 Gy in
35 fractions to the whole prostate. The experimental group
received 77 Gy to the whole prostate with an additional integrated
boost to the MRI-defined macroscopic tumour to a total dose of
95 Gy. The suspected benefit on five-year freedom from biochem-
ical failure was at least 10% for the experimental group.
C. Zamboglou et al. / Radiotherapy and Oncology 123 (2017) 472–477 473Radioactive-labelled tracers targeting the prostate specific
membrane antigen (PSMA) have gained interest. PSMA is a
membrane-bound enzyme and has a higher expression in malig-
nant prostate tissue compared to benign prostate tissue [8,9]. Pre-
liminary studies have illustrated the potential for PSMA PET/CT in
the detection of primary PCa based on histology reference [10,11].
Our group compared mpMRI with PSMA PET/CT for GTV delin-
eation in patients with primary PCa. In half of the patients dis-
crepant results were observed [12]. Three studies compared
mpMRI and PSMA PET/CT with histology after prostatectomy in
patients with primary PCa. PSMA PET/CT outperformed mpMRI
for PCa detection in all three studies [13–15].
Two studies compared the volumes of mpMRI and PSMA PET
derived GTVs [12,16]. Both studies observed that PET based GTVs
were larger than GTVs based on mpMRI. A focal dose escalation
on larger GTVs implies a potential increase in toxicity for rectum
and bladder.
The aim of this RT planning study was to demonstrate the tech-
nical feasibility of intensity modulated radiation therapy (IMRT)
focal dose escalation on 68Ga-HBED-CC PSMA PET/CT derived GTVs
(GTV-PET) in patients with primary PCa. Furthermore, we calcu-
lated TCPs and the normal tissue complication probability (NTCP)
for rectum and bladder.Methods and materials
Patients
The study cohort consisted of 10 patients with intermediate (3
patients) to high-risk (7 patients) PCa [17] who had PSMA PET/CT
scans prior to radical prostatectomy. In a previous study [10] a
voxel-level comparison between PSMA PET and histology was per-
formed in 9 of the 10 patients. Their characteristics are described in
Supplementary Table 1. Written informed consent was obtained
from each patient, and the institutional review board approved this
study.PET/CT imaging
A detailed description of our 68Ga-HBED-CC-PSMA PET/CT
imaging protocol can be found in Zamboglou et al. [12] for PSMA
PET/CT scans using the ligand 68Ga-HBED-CC-PSMA [18] were
either performed with a 64-slice GEMINI TF PET/CT or a 16-slice
GEMINI TF BIG BORE PET/CT (both Philips Healthcare, USA). The
scanners were cross-calibrated to ensure the compatability of the
quantitative measurements. Patients underwent a whole body
PET scan 1 h post injection. The uptake of 68Ga-PSMA-HBED-CC
was quantified by standardized uptake values (SUV, regional tracer
concentration normalized by injected dose per body weight).Image co-registration
After fixation, the resected prostate underwent an ex-vivo CT
scan in a customized localizer (according to our protocol [15]).
Subsequently, whole-mount step sections were cut every 4 mm
using an in–house cutting device and processed by an experienced
pathologist (VD). The sections obtained had the same cutting angle
and position as the corresponding ex-vivo CT slices. Histology sec-
tions were registered on ex-vivo CT images and PCa contours were
transferred onto the CT images. The contours were expanded by
2 mm in both Z-axis directions to create GTV-histo. Taking into
account the non-linear shrinkage and distortion of the prostatic
gland after resection, ex-vivo CT (including GTV-histo) was regis-
tered on in vivo CT (from PSMA PET/CT scans) by careful manual
coregistration with additional non-rigid deformation (Fig. 1). Thealignment of in vivo CT and PET scan was already given by the
hardware coregistration of the combined PET/CT scanners.Generation of contours
According to our previous work [10], GTV-PET was created
semi-automatically using a threshold of 30% of SUVmax within
the prostate in the RT planning system iPLAN RT image 4.1 (Brain-
LAB, Germany). Subsequently, in vivo CT (including GTV-histo and
GTV-PET) was transferred in RT planning system Oncentra v4.3
(Nucletron, The Netherlands) and contours for the prostate, semi-
nal vesicles, and surrounding organs at risk were generated. Clini-
cal target volume 1 (CTV1) was defined as the prostate and the
seminal vesicles. CTV2 was defined as the prostate and half of
the seminal vesicles (high risk patients) or the basis of the seminal
vesicles (intermediate risk patients). CTV1/2 and GTV-PET were
enlarged by an isotropic margin of 4 mm to create the planning tar-
get volumes (PTVs): PC1, PC2 and PC3, respectively.IMRT planning
All CT images and contours were imported into Eclipse v13.5
(Varian, USA) and Rapid Arc IMRT treatment plans were created.
The two arms of the FLAME trial [7] were simulated for each
patient. The standard arm received 52.8 Gy in 24 fractions on
PC1 and 24.3 Gy in 11 fractions on PC2 (Plan77). The experimental
arm received a concomitant boost to the PC3 with a dose of 95 Gy
in 35 fractions (Plan95). At least 70 Gy had to be delivered to 99% of
PC2 in both arms. The D2% of PC3 had to be 105% of the pre-
scribed dose (99.75 Gy) [19]. However, a D2% >99.75 Gy was
accepted as a minor deviation.
Dose constraints for rectum and bladder were taken from the
FLAME protocol [7]. Penile bulb, small bowel and sigma dose con-
straints were taken from the QUANTEC review [2,20,21] and have
been adapted to the FLAME-trial fractionation schemes. For
detailed restriction doses please see Supplementary Table 2.
Adherence to the dose constraints for the organs at risk had the
highest priority.Radiobiological treatment plan evaluation
The calculations were performed in the research version of BIO-
TOP/BIOSPOT available in our department (provided by Pi-medical,
Greece). For this purpose all DICOM RT data (images, structures,
plans and doses) have been transferred from Eclipse to BIOSPOT.
The summation of 3D dose distributions and EQD2 values as well
as TCP and NTCP calculations were performed at the voxel level.
For Plan77 and Plan95 the differential dose-volume histogram
(DDVH) for GTV-histo was generated and the corresponding aver-
age dose defined as the volume-weighted average dose (D) was
calculated.
For TCP modelling a radiobiological model based on the linear
quadratic (LQ) Poisson model [22–29] was used (see Supplemen-
tary Material A). TCP calculations were performed for both Plan77
and Plan95 based on GTV-histo (TCP-histo) under the assumption
that GTV-histo represents the true target and true clinical
response, respectively.
To account for the diversity of parameters which were used for
TCP calculations in current literature, we performed our TCP-histo
calculation using 15 different parameter value sets (see Supple-
mentary Material A). The following parameter ranges were used:
a/b = 1.2–4 Gy, [30]; and tumour cell density q = 105–2.8  108
cells/cm3 for intermediate and high-risk patients according to
[4,31,32]. Similar to [31] for each parameter value combination
the value of a was chosen in order to achieve an average
TCP-histo value of 70% across all patients when Plan77 was used.
Fig. 1. Co-registration and planning procedures. (A) shows one H&E stained prostatectomy specimen of patient 1. PCa tissue was delineated with black ink. (B) shows an axial
CT slice (PSMA PET/CT scan) including digitalized and registered histological information (GTV-histo, green contour). The prostate contour is marked in red. (C) shows the
fused 68Ga-HBED-CC-PSMA PET/CT scan, indicating PCa in the right lobe. In (D) the colourwash representation for Plan95 is presented. The GTV delineated with PSMA PET was
expanded in all directions with a 4 mm margin to create PC3, which is marked in red.
474 IMRT Dose Painting Using PSMA-PET/CTAdditionally, TCP-PET was calculated by taking GTV-PET as
the tumour volume. For the calculation of TCP-PET solely
parameter value set 1 was used: a/b = 1.93 Gy, a = 0.1335 Gy1,
q = 2.8  108 cells/cm3.
To calculate NTCP from non-uniform dose distributions the rel-
ative seriality model was used [24,33–39] (see Supplementary
Material B). For bladder a D50 = 80 Gy as EQD2 (symptomatic con-
tracture and volume loss), s = 1.3 and c = 2.59 were chosen in
accordance to [40]. For rectum a D50 = 80 Gy as EQD2 (for severe
proctitis/necrosis/stenosis/fistula, average of D50 values in [40–
44]), s = 0.75 were chosen according to [40]. The c-values
(c = 2.59 for bladder and c = 1.79 for rectum) were calculated based
on the listed k-values [36–38] (see Supplementary Material B). For
both organs an a/b of 3 Gy was assumed according to a recent
study [41].Statistical analysis
Statistical analysis was performed with MATLAB (MATLAB
R2014a, The MathWorks, USA) and Microsoft Excel 2010 (Micro-
soft, Redmond, USA). The Wilcoxon matched pairs signed-rank test
was used with a threshold for statistical significance of <0.05.Results
Mean volumes of GTV-PET and GTV-histo were 7.5 ± 4.8 ml and
5.4 ± 6.9 ml, respectively. This difference was not significant in
paired comparison (p = 0.2). In all 10 patients, the target volume
objectives as well as the OAR dose constraints were met with theexception of a minor deviation (D2% in PC3 > 99.75 Gy) in Plan95
in 7 patients.
For Plan77 and Plan95 the volume weighted average doses in
GTV-histo were 76.8 ± 3 Gy and 96.9 ± 1 Gy, respectively. Fig. 2
shows the averaged dose volume histograms (DVHs) for the rele-
vant volumes and Supplementary Fig. 1 shows for each patient
the DVHs for Plan95 in GTV-histo and GTV-PET.
Average TCP-PET were 55% (range: 27–82%) for Plan77 and 100%
(range: 99–100%) for Plan95. Average TCP-histo values for all param-
eter value sets were 70% (range: 15–97%) and 96% (range: 78–100%)
for Plan77 and Plan95, respectively. TCP-histo and TCP-PET were sig-
nificantly higher for Plan95 compared to Plan77 (p < 0.0001), respec-
tively. SupplementaryTables3 and4 showadetailedpresentationof
the TCP-values. Mean NTCPs for bladder in Plan77 and Plan95 were
3 ± 1.2% and 2.9 ± 0.9%, respectively. The average NTCPs for rectum
in Plan77 and Plan95 were 0.9 ± 0.4% and 1 ± 0.6%, respectively. No
significant differences in rectal (p = 0.563) and bladder (p = 0.3)
NTCPs were observed between the 2 plans.
Discussion
In the current study we examined the technical feasibility of
PSMA PET/CT guided dose painting using the prescription doses
and dose constraints of the FLAME trial (experimental and standard
arm). TCP calculation was performed on PET information (GTV-PET)
as well as on the registered histological information after prostate-
ctomy (GTV-histo). The latter should demonstrate the actual
tumour location and likewise should predict the true response.
Several RT planning studies demonstrated an increased thera-
peutic ratio when an intraprostatic boost was delivered to MRI or
Fig. 2. Averaged DVHs. An averaged DVH, over all 10 cases, for GTV-histo, GTV-PET, bladder and rectum is shown. The dashed line represents Plan95 and the continuous line
Plan77.
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included GTV boosts based on mpMRI (FLAME [7] and HEIGHT
(clinicialtrials.gov NCT0141132)). Both studies delivered a GTV
boost of 95 Gy with whole prostate doses in the range of 76–
77 Gy. However, three studies compared mpMRI with PSMA PET/
CT for detection of primary PCa based on histology Refs. [13–15]
and reported higher sensitivities (49–75%) and specificities (87–
95%) for PSMA PET/CT.
Our group showed that PSMA PET-based volumes (mean 11 ml)
were significantly larger compared to MRI-defined volumes (mean
6 ml) [12]. This observation was also reported by Thorwarth et al.
[16]. Thus, boosting of PSMA PET-defined targets may become
more challenging than boosting on MRI-defined GTVs. In the pre-
sent study, mean GTV-PET was larger than mean GTV-histo
(7.5 ml vs. 5.4 ml), although this difference was not significant in
paired analysis. This finding may be explained by the specificity
of 65% when GTV-PET is delineated using a threshold of an
intraprostatic SUVmax of 30% [15]. This threshold was derived
from a voxel-wise correlation between PSMA PET/CT and PCa in
histology using receiver operating characteristic analysis demand-
ing a sensitivity 0.9 [10].
However, in this study the dose constraints and prescription
doses of the FLAME trial [7] were applied and maintained for all
patients. For Plan95 a D2% > 99.75 Gy (EQD2 = 121.3 Gy, a/
b = 1.93 Gy) in PC3 [19] was accepted as a minor deviation in 7
patients. A recent study [47], applied a cumulative dose of
EQD2 = 140.9 Gy (a/b = 1.93 Gy) to GTV defined by mpMRI using
1 fraction HDR-brachytherapy in combination with hypo-
fractionated external beam radiation therapy. With a median
follow-up of 18 months none of the patients experienced acute uri-
nary retention and only three patients (20%) experienced acute
grade 2 GU toxicity. Further studies with longer follow-up are nec-
essary to assess whether the delivery of increasing doses leads to
increased genitourinary toxicity (e.g. urethral stricture). In the cur-
rent study, NTCPs for bladder and rectum did not differ between
dose escalation and standard RT plans using the relative seriality
model. These results have been confirmed using the Lyman-
Kutcher-Burman model [44] with the same a/b and D50 values.
For the parameters m (slope) and n (volume) the values of 0.13and 0.12 for bladder and 0.14 and 0.105 rectum have been used,
respectively.
Niyazi et al., simulated a dose escalation based on cholin PET
defined GTVs and found a dependence of different parameter val-
ues (a/b, c50) on TCP [48]. To account for this issue, we used 15
parameter sets which included a combination of suggested values
from current literature. The observed variance between the TCP-
histo values for the different parameter value sets was low in our
study. The average standard deviation over all datasets was 0.5%
and 0.2% for Plan77 and Plan95, respectively.
Fig. 1 shows an exemplary case where PSMA PET failed to detect
three small PCa lesions (<5 mm) in the left lobe. The lack of detec-
tion of small PCa lesions may lead to sensitivities <75% [13–15] and
may be explained by PET resolution limitation [46]. In a previous
study, our group performed a voxel-level correlation between
PSMA PET/CT and PCa in histology [10]. A moderate correlation
(R2  50%) was reported in 44% of the patients. Consequently, the
present study addressed the question whether a lack in PCa detec-
tion has an influence in TCP-histo. A moderate correlation between
PSMA PET/CT and PCa may explain the difference between GTV-
histo and GTV-PET in the DVHs of patient 6 and 8–10 (see Supple-
mentary Fig. 1). Despite this, we could show high TCP-histo values
for Plan95 (in mean 96%). Moreover, there was no significant differ-
ence observed when TCP was calculated on PET (TCP-PET) or his-
tology information (TCP-histo). However, patient 9 and 10 had
lower TCP-histo values compared to the other patients in Plan95.
This observation can be explained by the low coverage of GTV-
histo by PSMA PET, since 76% and 88% of GTV-histo overlapped
with PC3 in patient 9 and 10, respectively. On the other hand,
74% and 85% of GTV-histo overlapped with PC3 in patient 6 and
8. Both had an average TCP-histo value of 100%. The total volume
of GTV-histo in patient 6 (2.7 ml), 8 (3.1 ml), 9 (40.5 ml) and 10
(31.4 ml) could explain the difference in TCP-histo values, as TCP
decreases with the absolute volume of GTV-histo which is not
boosted. Our findings showed the feasibility of PSMA PET/CT as a
guidance tool for dose painting in primary PCa. Future studies
should assess whether the additional usage of mpMRI information
can lead to a further improvement of TCP, especially in patients
with large tumours.
476 IMRT Dose Painting Using PSMA-PET/CTIkeda et al. simulated the effect of intrafraction prostate motion
on dose coverage of the boost volume during simultaneous boost
intensity-modulated RT [49]. Since the majority of published plan-
ning studies did not investigate this effect it remains generally
unknown how sensitive the coverage of GTV-histo is for dose
painted PTVs to intrafractional motion. Recently, Rowe et al.
defined a dominant intraprostatic lesion (DIL) as the lesion with
the highest Gleason score [50]. Since data regarding the parame-
ters to define a potential DIL are inconclusive [51,52], no separate
analysis of boosting only the DIL was performed in our study. An
important issue of our study is the uncertainty in the correlation
of PET/CT and histopathology (e.g. manual registration between
ex-vivo and in vivo CT to account for non-linear shrinkage of the
prostate after prostatectomy). Thus, it could not be excluded that
moderate coverage of GTV-histo by GTV-PET is partly a conse-
quence of mismatch in coregistration or incomplete histopatholog-
ical coverage instead of poor tracer performance.
Conclusion
In patients with primary PCa, IMRT dose escalation to PSMA
PET/CT defined GTVs is technically feasible, achieving significantly
higher TCPs based on co-registered histology without higher NTCPs
compared to normal fractionation.
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